Business Context and Reporting Period
PMGC Holdings Inc. (Nasdaq: ELAB), a Nevada corporation, filed this Form 8-K on March 24, 2026. The report details a material definitive agreement entered into by Northstrive Biosciences Inc., a wholly owned subsidiary of the Company.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial disclosure relates to a specific contractual obligation:
- Monetary Consideration: The Company is required to pay MOA Life Plus Co., Ltd. a monetary value upon execution of the agreement and within 30 days of the effective date. The specific amount is not disclosed in the summary text.
Material Changes
The primary material change is the execution of a Third Amendment to a License Agreement with MOA Life Plus Co., Ltd. (MOA), originally dated April 30, 2024. Key changes include:
- Amendment of Exhibit C: The amendment restates Exhibit C in its entirety.
- Milestone Updates: Updates were made to the achievement of certain milestones for the "Field," specifically regarding phases for pre-clinical trials and events associated with Investigational New Drug (IND) Applications.
- Timeline Adjustments: The timelines for achieving the aforementioned milestones have been revised.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, general outlook, or a discussion of risks beyond the context of the amended agreement. The agreement involves pre-clinical trial phases and IND applications, implying ongoing development risks inherent to the biotechnology sector. The full text of the Third Amendment is attached as Exhibit 10.1 and contains the complete terms.
Investor Verification Checklist
- Review Exhibit 10.1 to determine the exact monetary consideration payable to MOA Life Plus Co., Ltd.
- Verify the specific revised timelines for pre-clinical trial phases and IND Application events in the amended Exhibit C.
- Assess the impact of the revised milestones on the Company's future cash flow requirements and development schedule.